Accelerate your diagnostic development
Abcodia is a specialist company engaged in the validation and discovery of biomarkers linked to age related diseases. Our mission is to help every individual lead longer healthier lives.
Commercial organisations and academic groups that are engaged in the validation and discovery of biomarkers for the screening, diagnosis and prognosis of disease, can obtain results significantly quicker by partnering with Abcodia.
A unique serum bank
In 2001, the UKCTOCS trial began collecting serum samples from over 200,000 women volunteers; this serum bank now contains over 5 million longitudinal serum samples. In addition to the serum, there is a comprehensive database of phenotypic, demographic and disease incidence for each volunteer. The serum bank and our strong bioinformatics capability makes Abcodia an ideal partner for any organisation seeking to validate or discover new biomarkers.
Click here for more information about how the serum biobank was created and the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
A collaborative approach
We
passionately believe that the best outcomes are gained through collaboration.
To ensure the best chance of success, we harness our network of technology
collaborators, commercial diagnostic partners and work closely with
UCL and other academics. More
Open to everyone
Abcodia
is keen to work with commercial and non-commercial organisations alike.
We have a flexible approach and business model that allows our collaborators
to make use of this unique resource. More
Get in touch
To find out more about what Abcodia can offer and collaboration opportunities,
please contact us
Email: info@abcodia.com
Latest News
Abcodia and BIOUNIVERSA collaborate on BAG3 biomarker for the early detection of pancreatic cancer.
23 April
2012 Abcodia, a biomarker validation company, has today announced a
collaboration with BIOUNIVERSA Srl, a spin off from the University of
Salerno, which aims to advance the development of the BAG3 protein biomarker
for use in the early detection of pancreatic cancer. More.
Invitation for proposals for the validation of cancer screening biomarkers from SMEs and Academics.
17 April
2012 Abcodia is inviting proposals from SME and Academic institutions
to access the serum biobank for the validation of biomarkers for the
early detection of biomarkers and will work with partners to develop
and commercialise novel biomarkers. Working with Abcodia has a great
number of benefits and we believe will improve the chances of a successful
outcome. More.
Abcodia Seeks Collaborations for Biomarkers of Breast Cancer.
16 April
2012 Abcodia is extending its biomarker initiatives beyond pancreatic
and colorectal cancers and is now seeking collaborators working in the
breast cancer field. We are particular interested in partners who
are looking to discover or validate biomarkers for early diagnosis and screening. More.
Abcodia and VolitionRX collaboration advances the discovery of blood based biomarkers for cancer
17 February
2012. Abcodia has today announced a collaboration with life sciences
company VolitionRx which will advance the development of biomarkers
for the early detection of cancer. More.
